Cost-effectiveness of treatment for chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 255-258

  Koff, Raymond S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chronic hepatitis C; Combination therapy; Computer simulation; Cost effectiveness analysis; Decision analysis; Empirical therapy; Interferon monotherapy

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; COMPUTER SIMULATION; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEPATITIS C; HUMAN; LIVER BIOPSY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; RETREATMENT;

EID: 0033430268     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80412-7     Document Type: Conference Paper

References (12)

1. Koff RS. Therapy of chronic hepatitis C: cost-effectiveness analysis. Hepatology 1997: 26 (Suppl 1): 152S-155S.
2. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994: 160: 268-272.
3. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995: 22: 1863-1873.
4. Wong JB, Bennett WG, Koff RS, Pauker SO. Pretreatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA 1998: 280: 2088-2093.
5. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997: 127: 855-865.
6. Kirn WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997: 127: 866-874.
7. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepatitis 1998: 5: 313-321.
8. Wong JB, McHutchison JG, Poynard T, Ling MH, Albrecht JK, Pauker SG for the IHIT Group. Cost-effectiveness of initial ribavirin/interferon alpha-2b for chronic hepatitis C. Gastroenterology 1999 (abstract, in press).
9. McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of retreatment with consensus interferon for chronic hepatitis C. Hepatology 1997: 26: 421A.
10. Wong JB, Davis GL, Pauker SG. Cost-effectiveness of ribavirin/ interferon alpha-2b after interferon relapse in chronic hepatitis C. Hepatology 1998: 28: 591A.
11. Kim WP, Poterucha JJ, Dickson ER, Gross JB. Economic analysis of interferon/ribavirin treatment in patients with chronic hepatitis C who relapse following initial interferon therapy. Gastroenterology 1998: 114: A1274.
12. Kim WR, Poterucha JJ, Dickson ER, Gross JB Jr. Cost-effectiveness of interferon/ribavirin treatment among nonresponders to initial interferon therapy for chronic hepatitis C. Hepatology 1998: 28: 231A.